114 minutes
For many Americans, the most difficult questions about 9/11 were not about politics, military strategy or homeland security. They were questions about God, about evil and about the potential for darkness within religion itself. What was it we saw on Sept. 11? Was it the true face of evil? Was it the face of religion? And where, if one is a believer, was God on that tragic morning?
No overview available.
86 minutes
When the Twin Towers fell on September 11, 2001, among the thousands killed was the one man who may have known more about Osama bin Laden and Al Qaeda than any other person in America: John O'Neill.
No overview available.
No overview available.
No overview available.
55 minutes
In December 2001, as American forces blasted mountain hideouts in the Tora Bora region of Afghanistan, hundreds of Al Qaeda soldiers fled seemingly disappearing into thin air. In this 2002 documentary, FRONTLINE investigates what happened to the fighters who survived.
No overview available.
Each year, six thousand Americans lose their lives on the job. Tens of thousands more are seriously injured or exposed to deadly poisons and carcinogens in the workplace. Yet if one of those workers dies on the job due to a company's willful disregard for federal safety regulations, the maximum penalty his employer faces is just six months in prison. Are America's workplace safety laws tough enough? And are companies being held responsible for protecting the safety of their employees? FRONTLINE investigates workplace safety in one of America's most dangerous industries.
No overview available.
No overview available.
No overview available.
No overview available.
No overview available.
No overview available.
No overview available.
No overview available.
No overview available.
No overview available.
55 minutes
Through interviews with consumers, legislators, scientists, top industry leaders and analysts, "The Other Drug War" examines the efforts of states like Maine and Oregon to control escalating drug costs in the face of strong opposition from the pharmaceutical industry. The program also explores the tension between the high cost of scientific innovation and society's need to keep drugs and health care affordable.
No overview available.